Skip to main content
. 2021 Jan 11;5:PO.20.00265. doi: 10.1200/PO.20.00265

FIG 3.

FIG 3.

Targetable oncogene fusions identified in KRASWT pancreatic adenocarcinoma in the Moffitt Cancer Center (MCC100) and independent cohorts (AACR GENIE and TCGA). Targetable fusions were reported across all three cohorts at an incidence of at least 19% among KRASWT pancreatic adenocarcinoma patients.